Given that both SPOP hotspot and non‐hotspot mutant cells are hypersensitive to the BET and CBP/p300 dual inhibitor, NEO2734, these findings provide a strong rationale for the inclusion of patients with SPOP‐mutated PCa in clinical studies of NEO2734. Here, EP300 is linked to posterior cortical atrophy.